SL BIO is advancing the frontiers of immunotherapy through the application of gamma delta (γδ) T cell technology, licensed from JY Biomedical. This platform leverages the innate immune surveillance properties of γδ T cells to explore precision-driven strategies in cancer immunology.

 

Gamma delta (γδ) T cells are a distinct subset of T lymphocytes with the capacity to recognize cellular stress markers independently of classical antigen presentation. This enables them to respond to abnormal cells, such as transformed or infected cells, in a manner that bridges innate and adaptive immunity. Their unique biology and broad tumor-recognition potential have made them a focus of increasing interest in next-generation immunotherapy research and investigational development.

​

Developed through years of focused research and manufacturing refinement, the γδ T cell platform is supported by a U.S. FDA Drug Master File filing (DMF #041080), providing a regulatory framework for quality transparency.

​

In collaboration with Taipei Medical University, JY Biomedical continues to investigate the role of γδ T cells through academia-industry partnerships. Preclinical research to date has demonstrated promising cytotoxic activity by unmodified γδ T cells across a range of tumor types, including brain and pancreatic.

​

At SL BIO, we are expanding this foundation through translational research, scientific collaboration, and disciplined development. Our goal is to responsibly advance γδ T cell platforms that contribute to the evolving landscape of immune-based oncology innovation.